Journal
BLOOD
Volume 137, Issue 16, Pages 2129-2130Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021011273
Keywords
-
Categories
Ask authors/readers for more resources
This study reveals how HSC subpopulations contribute to MPN pathogenesis and are perturbed under pegIFN therapy.
In this issue of Blood, Rao et al reveal important insights into how hematopoietic stem cell (HSC) subpopulations contribute to myeloproliferative neoplasm (MPN) pathogenesis, and how these populations are perturbed in the setting of pegylated-interferon (pegIFN) therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
